ALSO NOTED: Teva, Barr get OK to sell Fosamax copies; Ranbaxy wins FDA nod for copycat Nexium;

> Teva and Barr Pharmaceuticals both got FDA approval for their generic versions of Merck's osteoporosis drug Fosamax, which went off patent yesterday. Report

> India's Ranbaxy got the tentative FDA nod for its copycat form of AstraZeneca's Nexium heartburn pill, which is still under patent. Report

> Millennium Pharmaceuticals posted fourth-quarter profits of $41.06 million on revenues of $181.19 million. Report

> Wyeth hired Timothy Cost to be senior vice president for corporate affairs; previously, cost handled corporate affairs at ARAMARK. Report

> Swiss-based Octapharma is moving its U.S. headquarters to a 15,000-square-foot facility in Hoboken, NJ. Report

> Biogen Idec reported a big boost in quarterly profits, largely due to strong sales of its multiple sclerosis drugs and a cancer med it markets jointly with Genentech. Report

> French authorities are investigating GlaxoSmithKline and Sanofi Pasteur over an anti-hepatitis B vaccination campaign in the 1990s. At issue is whether the companies fully disclosed the shot's potential side effects. Report

> A new blend of a genetically modified chimp adenovirus and a malaria gene is proving promising as a potential vaccine against malaria. Report

> Speculation over the prospective acquisition of CeNeS continued to mount as the company's shares shot up 70 percent yesterday. Report

> AstraZeneca is shaking up its global R&D efforts, planning to slash some 300 research positions at a major complex in the U.K. Report

> The most efficient drug development programs will rely on contributions from a variety of companies, with partnerships and outsourcing providing unique expertise to advance new therapies, according to a new study from Tufts Center for the Study of Drug Development. Report

And Finally... Prescription mac-and-cheese? Kraft Foods is working on products that will contain plant oils to kill intestinal parasites such as tapeworms. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.